1. Introduction

Cross-Border Decentralized Trial Investigator Accountability concerns the legal responsibility of clinical trial investigators, principal investigators, sub-investigators, healthcare professionals, research institutions and trial sponsors when a decentralized clinical trial (DCT) is conducted across multiple countries.

A decentralized clinical trial is a clinical research arrangement in which some or most trial activities take place outside traditional clinical trial sites. Instead of requiring participants to attend a central hospital or research institution, investigators may supervise trial activities through:

Telemedicine consultations and remote medical examinations.

Home-based clinical assessments.

Digital informed consent (e-consent).

Wearable devices and remote monitoring technologies.

Direct-to-patient investigational medicinal product delivery.

Local laboratories and diagnostic centres.

Electronic clinical outcome assessments.

Remote safety monitoring and adverse-event reporting.

Cloud-based clinical trial data management.

When such trials cross national borders, accountability becomes more complicated because the investigator, participant, sponsor, research institution, technology provider and regulatory authority may be located in different jurisdictions.

The central legal question is: Who is legally responsible when a participant suffers injury, informed consent is defective, safety information is ignored, trial data are manipulated, or a medical decision is made remotely by an investigator located in another country?

The answer depends on the applicable national laws, trial authorisations, investigator agreements, professional duties, ethical standards and the actual allocation of decision-making responsibilities.

2. Legal nature of investigator accountability

Investigator accountability is not merely an administrative obligation. It involves several overlapping legal duties.

A critical distinction must be maintained:

Investigator responsibility: Primarily concerns participant protection, clinical decisions, protocol compliance and supervision of delegated trial activities.

Sponsor responsibility: Primarily concerns trial initiation, financing, overall management, monitoring systems and oversight of contracted service providers.

Institutional responsibility: Concerns research governance, facilities, staff supervision, ethics compliance and institutional safety systems.

Local healthcare provider responsibility: Concerns the clinical services and professional activities actually undertaken by that provider.

Delegating an activity does not automatically eliminate the original responsible party's legal obligations.

The European Commission's 2025 recommendation on decentralized clinical trials expressly emphasizes that investigators retain responsibility for trial-related medical decisions and participant protection within their areas of responsibility.

Public Health+1

3. International legal and regulatory framework

A. ICH Good Clinical Practice – E6(R3)

The International Council for Harmonisation (ICH) Good Clinical Practice framework is central to international investigator accountability.

ICH E6(R3) addresses:

Investigator qualifications and responsibilities.

Participant rights, safety and well-being.

Informed consent procedures.

Delegation and supervision.

Medical care during clinical trials.

Protocol compliance and deviations.

Essential documents and clinical records.

Data integrity and traceability.

Risk-based quality management.

Sponsor and investigator oversight.

The current Principles and Annex 1 became effective in the EU on 23 July 2025. Annex 2, which specifically addresses decentralized and pragmatic trial designs, has been adopted but is scheduled to become effective in the EU on 15 January 2027. Therefore, the two components must not be treated as having identical effective dates.

European Medicines Agency (EMA)+1

Legal significance: An investigator cannot avoid responsibility merely because a clinical assessment is performed through a digital platform, at a participant's home or by a third-party healthcare provider.

B. European Union Clinical Trials Regulation

The EU Clinical Trials Regulation (Regulation (EU) No 536/2014) establishes a harmonized framework for clinical trials conducted within the EU.

Important requirements include:

Prior authorization of clinical trials.

Ethics review and participant protection.

Investigator and sponsor responsibilities.

Informed consent.

Safety reporting.

Trial documentation.

Inspection and regulatory enforcement.

Compensation arrangements for trial-related injury.

In decentralized trials, additional problems arise when a participant resides in one Member State while the investigator or sponsor is established in another.

The legal analysis must identify the Member State's applicable trial authorization, national professional rules and relevant requirements for remote healthcare.

C. United States regulatory framework

The principal US provisions include:

21 CFR § 312.60 – General responsibilities of investigators.

21 CFR § 312.61 – Control of investigational drugs.

21 CFR § 312.62 – Investigator recordkeeping and record retention.

21 CFR § 50 – Protection of human subjects and informed consent.

21 CFR § 56 – Institutional Review Boards.

21 CFR § 812.100 – General responsibilities of investigators conducting device investigations.

Under these provisions, investigators must protect trial participants, follow the investigational plan and maintain appropriate trial records.

FDA's September 2025 E6(R3) guidance also clarifies that sponsors retain ultimate responsibility for sponsor activities transferred to service providers. Thus, investigator accountability and sponsor accountability operate alongside one another rather than replacing one another.

September 2025+1

D. Indian regulatory framework

India provides an important jurisdictional example because international sponsors frequently conduct clinical research involving Indian participants.

The relevant framework includes:

New Drugs and Clinical Trials Rules, 2019.

Drugs and Cosmetics Act, 1940.

ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.

CDSCO regulatory requirements.

Institutional Ethics Committee requirements.

Digital Personal Data Protection Act, 2023, to the extent its relevant provisions are in force and applicable.

Applicable medical professional and telemedicine regulations.

The investigator must ensure that trial conduct complies with Indian authorization requirements, ethics approval, informed-consent obligations, compensation rules and applicable professional standards.

An overseas sponsor cannot assume that authorization in its home country automatically permits research involving participants in India.

4. Major dimensions of cross-border investigator accountability

A. Accountability for informed consent

Informed consent is one of the most important legal duties of a clinical investigator.

Decentralized trials frequently use electronic consent platforms, video consultations and remote identity verification. These methods can create difficulties concerning:

Whether the participant understands the research.

Whether the consent information is available in the participant's language.

Whether the participant has sufficient opportunity to ask questions.

Whether the person signing is actually the participant or authorized representative.

Whether consent was voluntary.

Whether withdrawal procedures are adequately explained.

Whether the digital consent record is authentic and accessible.

An investigator should not treat a digital signature as conclusive evidence of legally valid informed consent.

Example: An Indian participant joins a clinical trial operated by a US sponsor. The principal investigator is located in Singapore, and electronic consent is provided in English, although the participant has limited English proficiency.

If the participant does not understand the risks, the investigator may face liability for inadequate consent, depending on the applicable law and circumstances.

The responsibility includes ensuring that consent is understandable, properly obtained and documented before trial procedures begin.

B. Accountability for remote medical decisions

Remote medical decision-making creates jurisdictional and professional challenges.

Consider an investigator located in Australia who supervises participants in India through telemedicine.

Questions arise concerning:

Whether the investigator is legally permitted to provide medical services in India.

Whether registration or local professional authorization is required.

Which professional standards apply.

Whether emergency medical treatment is available locally.

Who is responsible for delayed diagnosis or treatment?

Whether remote assessment is clinically appropriate.

The investigator must distinguish between clinical research supervision and the practice of medicine in another jurisdiction.

A research agreement cannot override statutory licensing restrictions.

C. Accountability for delegated trial activities

Decentralized trials commonly involve third parties, including:

Home healthcare nurses.

Local physicians.

Mobile phlebotomy services.

Diagnostic laboratories.

Telemedicine platforms.

Digital health technology providers.

Clinical research organizations.

Delegation must be based on competence, training, documented authority and appropriate supervision.

For example, a local nurse may collect blood samples, but decisions concerning participant eligibility, significant clinical abnormalities and treatment-related medical judgments must remain with appropriately qualified and responsible medical personnel.

The European Commission's recommendation emphasizes that responsibilities should be documented and that medical decisions must remain under the control of the investigator responsible for them.

Public Health+1

D. Accountability for adverse events

Remote trials may make adverse-event detection more difficult because participants report symptoms through applications, wearable devices or electronic questionnaires.

Investigator duties include:

Receiving safety information.

Evaluating clinical significance.

Identifying serious adverse events.

Arranging appropriate medical intervention.

Reporting relevant events through required channels.

Documenting decisions and follow-up.

Communicating urgent safety information to the sponsor.

A failure to respond to a serious adverse-event notification may constitute professional negligence, regulatory non-compliance or breach of trial obligations.

The investigator's responsibility must be assessed alongside the sponsor's obligation to establish systems that make relevant safety information available promptly.

E. Accountability for digital data integrity

Cross-border decentralized trials may process enormous quantities of personal and clinical information.

Examples include:

Wearable-device readings.

Genomic information.

Blood-test results.

Electronic health records.

AI-generated clinical assessments.

Geolocation information.

Remote physiological monitoring.

Digital patient diaries.

Investigator accountability includes checking whether clinical data are sufficiently reliable for medical decisions and whether relevant findings are properly recorded.

An investigator should not blindly rely on an automated system where there are reasonable grounds to suspect inaccurate readings, missing information or technical malfunction.

Data integrity responsibilities also involve traceability, correction of errors, access controls and preservation of essential trial records.

F. Accountability for investigational medicinal products

Investigators must ensure proper control over investigational products, including:

Receipt and storage.

Temperature monitoring.

Distribution and administration.

Participant-specific dispensing records.

Dosage verification.

Product accountability.

Return or destruction of unused products.

Cross-border delivery creates additional risks involving customs clearance, import permissions, cold-chain failures and unauthorized distribution.

If a participant receives an incorrect dose because of inadequate supervision, liability may arise against the investigator, dispensing professional, sponsor or other responsible party, depending on the facts.

G. Accountability for artificial intelligence and automated systems

AI-assisted decentralized trials create new accountability problems.

For example, an AI system may:

Identify participants eligible for recruitment.

Predict adverse reactions.

Analyse wearable-device information.

Recommend changes in treatment.

Identify abnormal physiological measurements.

Generate automated safety alerts.

The investigator must determine whether an AI-generated recommendation is clinically reliable before relying on it for a medical decision.

A software provider's contractual responsibility does not automatically eliminate the investigator's professional duty to exercise appropriate clinical judgment.

Where an investigator ignores a clinically significant warning, or relies uncritically on an obviously defective system, negligence may arise.

5. Important case laws and judicial principles

There is currently no comprehensive body of reported appellate case law specifically addressing cross-border decentralized clinical trial investigators. However, established judicial decisions concerning medical negligence, informed consent, research participant protection and institutional responsibility provide important legal principles.

The following cases are particularly relevant.

Case 1. Grimes v. Kennedy Krieger Institute, Inc. (2001), 782 A.2d 807

Directly relevant to research accountability

Court: Maryland Court of Appeals, United States.

Facts:

The case involved research concerning lead exposure in residential environments. Children participated in research programmes designed to examine the relationship between environmental lead exposure and health risks.

The participants' families alleged that the researchers had failed to adequately protect children from foreseeable exposure to lead.

Legal issue:

Whether researchers conducting non-therapeutic human-subject research could owe enforceable duties of care to research participants.

Decision and principles:

The court recognized that research agreements and the relationship between investigators and participants could create duties of care.

It held that, in appropriate circumstances:

Research consent agreements can create contractual obligations.

A special relationship can arise between researchers and participants.

Researchers may have duties to protect participants from unreasonable harm.

Regulatory requirements can contribute to legally enforceable duties.

Researchers cannot necessarily transfer the entire responsibility for participant protection to participants themselves.

Application to decentralized trials:

This decision is particularly significant when participants are monitored remotely and investigators rely on third-party service providers.

An investigator cannot simply argue that the participant accepted the risks through electronic consent.

If the investigator knows that a remote monitoring arrangement creates foreseeable risks, reasonable protective measures may be required.

Case 2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Court: Supreme Court of India.

Facts:

The patient consented to a diagnostic procedure. However, the doctor performed additional surgical procedures without obtaining specific consent.

The doctor argued that the additional procedures were beneficial.

Legal issue:

Whether consent for one medical procedure authorizes a doctor to undertake additional procedures without obtaining further consent.

Decision:

The Supreme Court emphasized that valid consent must be voluntary and based on adequate information.

It established that:

The patient must possess the capacity to consent.

Consent must be voluntary.

The patient must receive adequate information about the nature and purpose of the procedure.

Consent for a diagnostic procedure does not automatically authorize therapeutic treatment.

Additional procedures generally require consent, except in narrowly defined emergency circumstances.

Application to decentralized trials:

Suppose an investigator obtains consent for remote blood monitoring but subsequently introduces additional invasive diagnostic procedures.

The original consent cannot automatically be treated as authorization for every subsequent procedure.

The investigator must ensure that the participant receives appropriate information and gives the required additional consent.

This judgment is particularly important for Indian investigators participating in international decentralized clinical trials.

Indian Kanoon+1

Case 3. Rogers v. Whitaker (1992) 175 CLR 479

Court: High Court of Australia.

Facts:

A patient underwent eye surgery and suffered a serious complication involving the previously healthy eye.

The surgeon had not adequately warned the patient about the risk.

Legal issue:

Whether doctors have a duty to disclose material risks associated with medical treatment.

Decision:

The High Court emphasized the patient's right to make an informed decision.

A risk may be material if:

A reasonable person in the patient's position would likely attach significance to it; or

The doctor knows or ought to know that the particular patient would likely attach significance to it.

Application to decentralized trials:

An investigator conducting remote consultations cannot assume that a standard electronic consent document adequately informs every participant.

For example, participants with particular medical conditions may need additional information about foreseeable trial-related risks.

The decision supports individualized risk communication rather than mechanical reliance on standardized digital consent forms.

Case 4. Sidaway v. Board of Governors of the Bethlem Royal Hospital [1985] AC 871

Court: House of Lords, United Kingdom.

Facts:

A patient suffered serious injury following surgery and alleged that the surgeon had failed to warn her about a material risk.

Legal issue:

Whether a doctor could be negligent for failing to disclose risks associated with proposed treatment.

Decision:

The House of Lords considered the relationship between medical professional standards and the duty to inform patients.

The case historically applied the Bolam approach to disclosure, although Lord Scarman supported a stronger patient-centred duty.

Application to decentralized trials:

Investigators should not assume that providing a generic digital consent form satisfies every applicable disclosure obligation.

The case is important for understanding the historical development of informed-consent law in the UK, although the modern legal position has been significantly clarified by Montgomery.

Case 5. Montgomery v. Lanarkshire Health Board [2015] UKSC 11

Court: Supreme Court of the United Kingdom.

Facts:

A pregnant patient with diabetes was not adequately warned about the risk of shoulder dystocia during vaginal delivery.

The risk materialized, causing serious injury to the child.

Legal issue:

Whether doctors must disclose material risks and reasonable alternative treatment options.

Decision:

The Supreme Court adopted a patient-centred standard of disclosure.

A doctor must take reasonable care to ensure that the patient is aware of:

Material risks of the recommended treatment.

Reasonable alternative or variant treatments.

Application to decentralized trials:

Investigators should disclose material research risks in a manner that enables participants to make meaningful decisions.

For example, a participant using an investigational digital therapeutic should receive information about foreseeable adverse effects, alternative treatment options and relevant uncertainties.

The case strengthens the argument that remote consent must be substantive rather than merely formal.

Case 6. Bolitho v. City and Hackney Health Authority [1998] AC 232

Court: House of Lords, United Kingdom.

Legal issue:

Whether professional medical opinion automatically protects a doctor from negligence liability.

Decision:

The court clarified that professional medical opinion relied upon to establish a standard of care must withstand logical analysis.

Application to decentralized trials:

An investigator cannot automatically defend a decision by claiming that a particular remote-monitoring practice was accepted by some professionals.

The court may examine whether the decision was logically defensible in light of the risks and available evidence.

Case 7. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

Court: Supreme Court of India.

Legal issue:

The distinction between civil medical negligence and criminal medical negligence.

Decision:

The Supreme Court explained that criminal liability for medical negligence requires a substantially higher threshold than ordinary civil negligence. Gross negligence or recklessness is relevant to criminal responsibility.

Application to decentralized trials:

An investigator's failure to respond to a remote safety alert may create civil or regulatory consequences.

However, criminal liability does not automatically follow from every clinical error or protocol deviation.

The degree of negligence, applicable statutory provisions, causation and evidence must be examined.

Bailii+2

6. Cross-border jurisdiction and applicable law

One of the most difficult questions is determining which country's law applies when an investigator and participant are located in different countries.

Consider this hypothetical:

Illustrative international clinical trial

United States

Trial sponsor and digital platform operator

Singapore

Principal investigator and coordinating research team

India

Participants, local laboratories and healthcare providers

Possible legal questions

Which country regulates the clinical trial?

Which law governs professional negligence?

Where can the participant bring a compensation claim?

Which ethics committee must approve the research?

Who controls access to medical records?

Which country can investigate the investigator?

The applicable legal principles may include:

A. Territorial jurisdiction: Each country may regulate clinical research, healthcare activities and professional conduct taking place within its territory.

B. Personal jurisdiction: Courts may exercise jurisdiction over investigators or organizations where the relevant jurisdictional requirements are satisfied.

C. Choice of law: Courts determine the governing law under their applicable conflict-of-laws rules. A contractual choice-of-law clause does not necessarily displace mandatory participant-protection legislation.

D. Professional jurisdiction: Medical practitioners may be subject to licensing and disciplinary proceedings in jurisdictions where they are registered or where their professional conduct falls within local regulatory authority.

E. Contractual jurisdiction: Investigator agreements, sponsor agreements and service-provider contracts may establish responsibilities and dispute-resolution procedures, subject to mandatory law.

F. Regulatory cooperation: Authorities may exchange information, inspect records and investigate suspected violations through applicable legal cooperation mechanisms.

An important principle is that the location of the sponsor's headquarters does not, by itself, determine the governing law of every participant injury.

7. Data protection and cross-border transfer accountability

Decentralized trials involve extensive cross-border movement of sensitive personal information.

The principal legal frameworks include:

Investigator accountability may arise where:

Medical records are transferred without a lawful basis.

Genetic information is disclosed improperly.

Participants are not adequately informed about data processing.

Remote monitoring platforms expose confidential information.

Unauthorized persons access trial records.

Data are transferred to countries without satisfying applicable transfer requirements.

An investigator is not automatically the controller or equivalent responsible entity for every processing activity. That status depends on the applicable law and the actual purposes and means of processing.

The sponsor, institution, investigator and technology provider may have different but overlapping obligations.

8. Civil, criminal and regulatory liability

Investigator accountability can arise through several legal mechanisms.

Important distinction: A protocol deviation does not automatically constitute negligence, and negligence does not automatically establish criminal liability. Each requires examination of its applicable legal elements.

9. Accountability for specific decentralized trial failures

The following examples illustrate how responsibility may be distributed.

The precise allocation depends on actual conduct, statutory duties, contractual arrangements and causation.

10. Investigator accountability and sponsor accountability

A major legal challenge is distinguishing the investigator's personal responsibilities from those of the sponsor.

The following comparison is useful:

The FDA's E6(R3) framework makes an important distinction: transferring sponsor activities to a service provider does not eliminate the sponsor's ultimate responsibility for those activities.

Similarly, the European decentralized-trial recommendations emphasize clearly documented responsibilities and continued investigator supervision.

September 2025+1

11. Regulatory enforcement mechanisms

Regulatory authorities may take action against investigators for serious violations.

Possible enforcement measures include:

Regulatory inspections.

Notices of non-compliance.

Corrective and preventive action requirements (CAPA).

Suspension of trial recruitment.

Suspension or termination of trial authorization.

Disqualification or restriction of investigators where legally authorized.

Professional disciplinary proceedings.

Civil compensation proceedings.

Criminal investigations where appropriate.

Restrictions on the use of unreliable clinical trial data.

In India, CDSCO and the relevant institutional and ethics oversight mechanisms have important roles in clinical trial regulation.

In the United States, the FDA has regulatory authority over investigator compliance within its statutory jurisdiction.

In the EU, national competent authorities enforce the Clinical Trials Regulation within their respective jurisdictions.

12. Defences and limitations of investigator liability

Investigators may rely on certain legal defences, depending on the jurisdiction.

A. Absence of negligence

An adverse outcome does not automatically establish negligence. The claimant generally needs to establish the relevant duty, breach, causation and damage.

B. Proper delegation

An investigator may demonstrate that a task was delegated to an appropriately qualified person with suitable instructions and supervision.

However, documentation of delegation alone is insufficient if the investigator failed to exercise required oversight.

C. Compliance with accepted professional standards

Evidence that the investigator followed an accepted and logically defensible professional standard may assist in defending a negligence claim.

D. Absence of causation

Even where a breach occurred, liability may not arise unless the required causal connection between the breach and the injury is established.

E. Unforeseeable events

Certain unexpected events may limit liability where they could not reasonably have been anticipated or prevented.

F. Participant-related factors

Participant non-compliance may be relevant to causation and damages, but it does not automatically eliminate an investigator's independent legal duties.

G. Statutory limitations

Limitation periods, jurisdictional restrictions and statutory liability provisions may affect the availability of remedies.

13. Reforms required for stronger investigator accountability

Cross-border decentralized research requires a more developed accountability system.

The following reforms would strengthen the framework.

1. International investigator responsibility standards: Develop clearer harmonized rules for investigators supervising participants in foreign jurisdictions.

2. Mandatory delegation registers: Maintain records identifying every person and organization performing trial-related activities.

3. Cross-border medical licensing clarity: Establish mechanisms for determining when remote trial-related medical services require local professional authorization.

4. Digital consent verification: Introduce reliable identity verification, language accessibility and consent-comprehension procedures.

5. Remote safety monitoring: Establish continuous and clearly allocated safety-alert management responsibilities.

6. AI accountability: Require appropriate human review of automated clinical recommendations and traceable decision records.

7. Cross-border data governance: Clarify controller, processor and investigator responsibilities for sensitive research information.

8. Emergency treatment arrangements: Ensure participants have access to timely medical intervention in their country of residence.

9. Mandatory insurance and compensation: Provide appropriate arrangements for research-related injury across jurisdictions.

10. Coordinated regulatory inspections: Improve cooperation between authorities where investigator activities and participant locations span several countries.

11. Institutional accountability: Require research institutions to establish effective oversight mechanisms for remote investigators and external healthcare providers.

12. Transparent contractual allocation: Ensure sponsor-investigator agreements clearly specify responsibilities, without attempting to contract out of mandatory legal duties.

14. Critical legal challenges

Several unresolved issues deserve particular academic attention.

Accountability fragmentation: Multiple organizations participate in a single trial, making it difficult to identify the responsible decision-maker.

Regulatory asymmetry: Different countries impose different requirements for consent, investigator qualifications and safety reporting.

Digital evidence: Electronic records may be stored in several countries, creating evidentiary and access difficulties.

Remote supervision: Investigators may supervise activities without physically observing the participant or service provider.

AI decision-making: It may be difficult to distinguish investigator negligence from defective software design or inadequate sponsor oversight.

Compensation difficulties: Participants may face practical obstacles when claiming compensation against overseas sponsors or institutions.

Conflicting professional standards: The investigator's home-country medical standards may differ from those applicable where the participant receives healthcare.

These challenges demonstrate that decentralized clinical trial accountability must be based on actual control, professional responsibility, statutory duties and the foreseeable risks of the research arrangement.

15. Conclusion

Cross-Border Decentralized Trial Investigator Accountability represents an important development in international biotechnology and clinical research law.

Traditional clinical trials generally operate through identifiable research institutions and physical trial sites. Decentralized trials distribute research activities across homes, laboratories, hospitals, digital platforms and multiple national jurisdictions.

This distribution does not eliminate the investigator's obligation to protect participants.

The most important legal principles are:

Participant safety must remain central to clinical research.

Informed consent must be genuine and legally valid.

Medical decisions must be made by appropriately qualified professionals.

Delegation must be documented and properly supervised.

Remote monitoring must provide reliable and actionable safety information.

Clinical data must remain accurate, secure and traceable.

Investigators and sponsors must retain their respective legal responsibilities.

Cross-border contractual arrangements cannot override mandatory statutory obligations.

The decisions in Grimes, Samira Kohli, Rogers v. Whitaker and Montgomery provide important foundations for understanding research participant protection and medical accountability.

Ultimately, the development of decentralized clinical research requires an accountability model in which technological innovation and international research cooperation remain compatible with individual rights, professional responsibility and effective legal remedies.

16. Important case-law reference list

Primary regulatory reading

EMA – ICH E6 Good Clinical Practice.

FDA – E6(R3) Good Clinical Practice Guidance.

European Commission – Recommendations on Decentralized Clinical Trials.

Health Canada – Decentralized Clinical Trial Guidance.

UK Government – Clinical Trial Roles and Responsibilities.

Academic qualification: The cited judgments are foundational or analogous authorities, not decisions directly determining liability in a cross-border decentralized clinical trial. Their application depends on the governing jurisdiction and the particular facts.